Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals’ (TLX) prostate cancer imaging agent receives a pass-through in the United States
- The pass-through payment status for Illuccix was granted by the U.S. Centres for Medicare and Medicaid Services
- Illuccix can be ordered by health care professionals in 128 pharmacies and is accessible to approximately 85 per cent of PET imaging sites across the US
- Meanwhile, Illuccix will become available to order for nationwide delivery to all PET imaging sites in Australia from July
- Telix Pharmaceuticals is up 7.94 per cent, trading at $4.62 at market close
Telix Pharmaceuticals’ (TLX) prostate cancer imaging agent has been granted a pass-through in the United States.
The pass-through payment status for Illuccix was granted by the U.S. Centres for Medicare and Medicaid Services (CMS).
From July 1, CMS and commercial health insurers will recognise the Healthcare Common Procedure Coding System (HCPCS) Level two code, which was assigned to Illuccix for reimbursement.
Illuccix is a positron emission tomography (PET) agent used in the diagnostic imaging of men with prostate cancer.
“This diagnostic agent is being rapidly adopted by physicians, who recognise its value in determining the extent of disease and to guide treatment decisions,” Group CEO of Telix Pharmaceuticals Dr Christian Behrenbruch said.
“With prostate cancer the most common cancer in American men, this reimbursement milestone is a win for patients and will facilitate even greater access to this tool which is quickly being considered as a potential standard of care.”
Illuccix can be ordered by health care professionals from 128 pharmacies and is accessible to approximately 85 per cent of PET imaging sites across the US. More sites will be added in the coming months.
Meanwhile, Illuccix will become available to order for nationwide delivery to all PET imaging sites in Australia from July.
From the first of the month, Medicare funding will cover the initial staging of intermediate to high-risk patients with prostate cancer.
“With the Australian launch of Illuccix timed to coincide with the commencement of Medicare funding, Telix and our distribution partner Global Medical Solutions Australia, are pleased to enable broad equity of access to PSMA-PET imaging for men with prostate cancer,” CEO Telix Asia Pacific Dr David Cade said.
Telix Pharmaceuticals was up 7.94 per cent, trading at $4.62 at market close.
